Filing Details

Accession Number:
0001725160-22-000034
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-14 21:10:22
Reporting Period:
2022-02-10
Accepted Time:
2022-02-14 21:10:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725160 Zentalis Pharmaceuticals Inc. ZNTL Pharmaceutical Preparations (2834) 823607803
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1819302 Alexis Pinto C/O Zentalis Pharmaceuticals, Inc.
1359 Broadway, Suite 1710
New York NY 10018
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-02-10 16,405 $0.00 22,931 No 4 A Direct
Common Stock Disposition 2022-02-14 614 $50.16 22,317 No 4 S Direct
Common Stock Disposition 2022-02-14 77 $50.75 22,240 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2022-02-10 38,489 $0.00 38,489 $52.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,489 2032-02-09 No 4 A Direct
Footnotes
  1. Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
  2. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.